NCT04489381: A trial that was reported late by Romark Laboratories L.C.
This trial has reported, although it was 966 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04489381 |
|---|---|
| Title | Phase 3, A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 19, 2020 |
| Completion date | Jan. 28, 2021 |
| Required reporting date | Jan. 28, 2022, midnight |
| Actual reporting date | Sept. 20, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 966 |